In this week’s edition of InnovationRx, we look at the havoc of generic drug tariffs, the companies looking to cash in on the coming peptide bonanza, the ongoing cyclosporiasis outbreak, Tempus’s acquisition of a cancer-testing company, and more. To get it in your inbox, subscribe here.
Browsing: tariffs
The Trump administration asked the United States trade court to pause a ruling that declared the president’s latest 10 per cent global tariffs unlawful while the government appeals, meaning importers would keep paying the levies while the legal fight continues.
The US recently imposed tariffs ranging from 10 percent to 12.5 percent on goods from 60 countries and regions, using alleged “forced labor” concerns as a pretext. The tariffs apply to Washington’s major trading partners, including a number of emerging economies that are deeply embedded in global supply chains. Beyond their immediate impact on trade…